Scolaris Content Display Scolaris Content Display

Pneumococcal conjugate vaccines for preventing vaccine‐type invasive pneumococcal disease and X‐ray defined pneumonia in children less than two years of age

Contraer todo Desplegar todo

Abstract

disponible en

Background

Pneumonia, caused by Streptococcus pneumoniae, is a major cause of morbidity and mortality among children in low‐income countries. The effectiveness of pneumococcal conjugate vaccines (PCVs) against invasive pneumococcal disease (IPD), pneumonia, and mortality needs to be evaluated.

Objectives

To update the 2004 review on the efficacy of PCVs in preventing vaccine‐serotypes IPD (VT‐IPD) , X‐ray defined pneumonia among HIV‐1 negative children, and other new outcomes.

Search methods

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, issue 1), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (1990 to Week 4 February 2009); and EMBASE (1974 to March 2009).

Selection criteria

Randomised controlled trials (RCTs) comparing PCV with placebo, or another vaccine, in children under two with IPD and clinical / radiographic pneumonia as outcomes.

Data collection and analysis

Two review authors independently identified studies, extracted data, and evaluated their corresponding risks of bias. Differences were resolved by discussion. Meta‐analysis used the inverse variance method.

Main results

We identified 11 publications from six RCTs conducted in Africa, US, Philippines and Finland where 57,015 children received PCV; while 56,029 received placebo or another vaccine. Seven publications provided high quality evidence on PCV efficacy against IPD and four provided moderate quality evidence against pneumonia. None of the five trials with all‐cause mortality data were powered to investigate this outcome. Only two trials have data on all‐cause admissions.

The main analysis for this review involved HIV‐1 negative children and used the pooled results of random‐effects model, intent‐to‐treat analysis (ITT).

Pooled vaccine efficacy (VE) for VT‐IPD was 80% (95% confidence interval (CI) 58% to 90%, P < 0.0001); all serotypes‐IPD, 58% (95% CI 29% to 75%, P = 0.001); World Health Organization X‐ray defined pneumonia was 27% (95% CI 15% to 36%, P < 0.0001); clinical pneumonia, 6% (95% CI 2% to 9%, P = 0.0006); and all‐cause mortality, 11% (95% CI ‐1% to 21%, P = 0.08). Analysis involving HIV‐1 positive children had similar findings.

Authors' conclusions

PCV is effective in preventing IPD, X‐ray defined pneumonia, and clinical pneumonia among HIV‐1 negative and HIV‐1 positive children under two years. The impact was greater for VT‐IPD than for all serotypes‐IPD, and for X‐ray defined pneumonia than for clinical pneumonia. An 11% reduction with a 95% CI of ‐1% to 21% and a P = 0.08 is compatible with reduction in all‐cause mortality.  

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Plain language summary

disponible en

Vaccines against overwhelming blood infection due to pneumococcus bacteria and lung infection (pneumonia) among children less than two years of age

Pneumococcus is one of the major causes of overwhelming blood infection and lung infection (pneumonia) among young children. Pneumococci resistant to antibiotics are now being found in great numbers worldwide which may reduce the effectiveness of recommended antibiotic treatment. Preventive measures like vaccination are needed. This review found two trials from the US, two from Africa, one from the Philippines, and another from Finland that involved 113,044 children less than two years of age. In these studies, PCV was able to prevent overwhelming pneumococcal blood infection and pneumonia.